AIDSWEEKLY Plus; Monday, September 13, 2004
Staff Medical Writers

According to a study from Japan, "Efavirenz (EFV) is metabolized by cytochrome P450 2136 (CYP2B6) in the liver. We analyzed the genotypes of CYP2B6 and their contribution to plasma EFV concentrations in 35 EFV-treated patients in the International Medical Center of Japan."

"The mean plasma EFV concentration of patients with CYP2R6 *6/*6 (Q172H and K262R) (25.4±7.5 mcM, ±SD, n=2) was significantly higher than that of patients with genotypes *6 heterozygote (9.9±3.3 mcM, n=10) or without alleles *6 (8.0±2.6 mcM, n=23) (p<0.0001)," K Tsuchiya and colleagues reported.

"To confirm our result," said investigators, "we further analyzed nine patients (three with high EFV concentrations and arbitrarily selected six with normal EFV concentrations) treated in Osaka National Hospital, and it resulted that the only three patients with the high concentrations were the *6/*6 holder."

"EFV dose could be decreased in those patients harboring the genotype to reduce toxicity with compromising potency, representing the first step of the Tailor-Made therapy of HIV-1 infection," Tsuchiya concluded.

Tsuchiya and colleagues published the results of their research in Biochemical and Biophysical Research Communications (Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6.

For additional information, contact S. Oka, International Med Center Japan, AIDS Clinical Center, Tokyo 1628655, Japan.

The publisher of the journal Biochemical and Biophysical Research Communications can be contacted at: Academic Press Inc. Elsevier Science, 525 B St., Ste. 1900, San Diego, CA 92101-4495 USA.

The information in this article comes under the major subject areas of Genomics & Genetics, HIV/AIDS, Antiretroviral Therapy, Prognostics and Drug Metabolism.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Tsuchiya K, Gatanaga H, Tachikawa N, et. al., "Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens", Biochem Biophys Res Commun. 2004 Jul 9;319(4):1322-6.

PubMED Related articles Search

040913
AW040904

Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.